Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai InnoStar Bio-tech CoSHSE:688710 +2.84%35 ROA % is 1.47% as of Mar. 2026, which is 75% below its 10-year median of 5.94. GuruFocus rates SHSE:688710 with a GF Score™ of 35/100. The stock has 8 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Shanghai InnoStar Bio-tech Co ranks worse than 65.34% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Shanghai InnoStar Bio-tech Co's annualizedNet Income for the quarter that ended in Mar. 2026 was ¥48.8 Mil.
Shanghai InnoStar Bio-tech Co's average Total Assets over the quarter that ended in Mar. 2026 was ¥3,312.9 Mil. Therefore, Shanghai InnoStar Bio-tech Co's annualized ROA % for the quarter that ended in Mar. 2026 was 1.47%.
The historical rank and industry rank for Shanghai InnoStar Bio-tech Co's ROA % or its related term are showing as below:
SHSE:688710'
s ROA % Range Over the Past 10 Years
Min: -0.94 Med: 5.94 Max: 7.21
Current: -0.73
During the past 7 years, Shanghai InnoStar Bio-tech Co's highest ROA % was 7.21%. The lowest was -0.94%. And the median was 5.94%.
SHSE:688710's ROA % is ranked worse than 65.34% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.78
vs SHSE:688710: -0.73
Shanghai InnoStar Bio-tech Co (SHSE:688710) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Shanghai InnoStar Bio-tech Co ROA % Related Terms
Shanghai InnoStar Bio-tech Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Shanghai InnoStar Bio-tech Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai InnoStar Bio-tech Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai InnoStar Bio-tech Co's ROA % distribution charts can be found below:
* The bar in red indicates where Shanghai InnoStar Bio-tech Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a ROA % of 1.47% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. This is 75% below median its historical median of 5.94. According to the industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #658 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 65.3%.
Is Shanghai InnoStar Bio-tech Co's ROA % too high?
Shanghai InnoStar Bio-tech Co's current ROA % of 1.47% is 75% below median its 10-year median of 5.94. The Drug Manufacturers industry median ROA % is 2.78. Shanghai InnoStar Bio-tech Co's value of 1.47% is 47.1% below this industry median. Based on the distribution chart, Shanghai InnoStar Bio-tech Co ranks #658 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai InnoStar Bio-tech Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai InnoStar Bio-tech Co's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #658 out of 1007 companies for ROA %. This places Shanghai InnoStar Bio-tech Co in the lower half of its industry. The industry median ROA % is 2.78. Shanghai InnoStar Bio-tech Co's value of 1.47% is 47.1% below this benchmark. While the company's 10-year median is 5.94 vs. the industry median of 2.78, Shanghai InnoStar Bio-tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.78, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai InnoStar Bio-tech Co's current ROA % of 1.47% is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai InnoStar Bio-tech Co's current ROA % is 1.47%, which is 75% below median its own 10-year median of 5.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai InnoStar Bio-tech Co stock overvalued right now?
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a current ROA % of 1.47%. The current ROA % is 1.47%, which is 75% below median its 10-year median of 5.94 and 47.1% below the Drug Manufacturers industry median of 2.78. Shanghai InnoStar Bio-tech Co's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Shanghai InnoStar Bio-tech Co (SHSE:688710), the current ROA % is 1.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai InnoStar Bio-tech Co Business Description
Shanghai InnoStar Bio-tech Co Ltd is a comprehensive research and development services (CRO) enterprise that specializes in providing biomedical non-clinical research services.
35GF Score
Get the complete analysis for SHSE:688710
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688710 has been successfully added to your 
